The aerospace sector's vast contributions often remain underappreciated by the general public, especially the intricate development of aircraft systems designed for highly specialized research. A prime example is the X-31 Enhanced Fighter Maneuverability Demonstrator.
Vaccine maker Vaxcyte, Inc. (PCVX) announced Thursday that the U.S. Food and Drug Administration (FDA) has cleared the Company's adult Investigational New Drug (IND) application for VAX-31, a 31-valent pneumococcal conjugate vaccine (PCV) candidate designed to prevent invasive pneumococcal disease (IPD).